🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  2. Matching placebo tablet, JNJ-67953964

    Janssen-Cilag International N.V.

    Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia

    phase 3 small molecule active

    1 trial

  3. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  4. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  5. MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine

    Sanofi Pasteur

    Meningococcal infection

    phase 3 small molecule active

    1 trial

  6. Mencevax ACWY

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    1 trial

  7. Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

    Sanofi Pasteur

    Meningococcal Infection

    phase 3 mab completed

    1 trial

  8. Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine

    Sanofi Pasteur

    Meningococcal Immunization

    phase 3 mab completed

    1 trial

  9. Meningococcal vaccine GSK134612

    GlaxoSmithKline

    Infections, Meningococcal

    phase 3 mab completed

    2 trials

  10. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  11. Metalyse 5 000 units (25 mg) powder for solution for injection

    Boehringer Ingelheim

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  12. Metformin

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  13. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  14. Metformina Uxa 850 mg comprimidos recubiertos con película EFG, El producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur, acondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo.

    The George Institute

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  15. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule terminated

    2 trials

  16. Methadone (100% dose)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  17. Methadone Treatment-As-Usual

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 small molecule active

    1 trial

  18. Methoxyflurane - Penthrox

    COLLEGIUM PHARMACEUTICAL, INC

    ST Elevation Myocardial Infarction

    phase 3 small molecule active

    1 trial

  19. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  21. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  22. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  23. Methylthioninium

    Shandong Suncadia Medicine Co.,

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  24. Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources